These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 12121507)
1. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507 [TBL] [Abstract][Full Text] [Related]
2. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone. Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M J Gastroenterol Hepatol; 2001 Nov; 16(11):1290-6. PubMed ID: 11903749 [TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic features of patients with primary malignant hepatic tumors seropositive for alpha-fetoprotein-L3 alone in comparison with other patients seropositive for alpha-fetoprotein-L3. Okuda H; Saito A; Shiratori K; Yamamoto M; Takasaki K; Nakano M J Gastroenterol Hepatol; 2005 May; 20(5):759-64. PubMed ID: 15853991 [TBL] [Abstract][Full Text] [Related]
4. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245 [TBL] [Abstract][Full Text] [Related]
5. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Sassa T; Kumada T; Nakano S; Uematsu T Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1387-92. PubMed ID: 10654799 [TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin. Dohmen K; Shigematsu H; Irie K; Ishibashi H Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467 [TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of Preoperative Hepatocellular Carcinoma With High Yamao T; Yamashita YI; Imai K; Umezaki N; Tsukamoto M; Kitano Y; Arima K; Miyata T; Nakagawa S; Okabe H; Hayashi H; Chikamoto A; Ishiko T; Baba H Anticancer Res; 2019 Feb; 39(2):883-889. PubMed ID: 30711971 [TBL] [Abstract][Full Text] [Related]
8. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients. Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007 [TBL] [Abstract][Full Text] [Related]
9. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Marrero JA; Feng Z; Wang Y; Nguyen MH; Befeler AS; Roberts LR; Reddy KR; Harnois D; Llovet JM; Normolle D; Dalhgren J; Chia D; Lok AS; Wagner PD; Srivastava S; Schwartz M Gastroenterology; 2009 Jul; 137(1):110-8. PubMed ID: 19362088 [TBL] [Abstract][Full Text] [Related]
10. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961 [TBL] [Abstract][Full Text] [Related]
11. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels. Hadziyannis E; Sialevris K; Georgiou A; Koskinas J Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Yamaguchi A; Isogai M; Kaneoka Y; Washizu J Clin Gastroenterol Hepatol; 2006 Jan; 4(1):111-7. PubMed ID: 16431313 [TBL] [Abstract][Full Text] [Related]
13. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Sterling RK; Jeffers L; Gordon F; Venook AP; Reddy KR; Satomura S; Kanke F; Schwartz ME; Sherman M Clin Gastroenterol Hepatol; 2009 Jan; 7(1):104-13. PubMed ID: 18849011 [TBL] [Abstract][Full Text] [Related]
14. Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects. Song P; Feng X; Inagaki Y; Song T; Zhang K; Wang Z; Zheng S; Ma K; Li Q; Kong D; Wu Q; Zhang T; Zhao X; Hasegawa K; Sugawara Y; Kokudo N; Tang W; Biosci Trends; 2014 Oct; 8(5):266-73. PubMed ID: 25382443 [TBL] [Abstract][Full Text] [Related]
15. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis. Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630 [TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Carr BI; Kanke F; Wise M; Satomura S Dig Dis Sci; 2007 Mar; 52(3):776-82. PubMed ID: 17253135 [TBL] [Abstract][Full Text] [Related]
17. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. Yamamoto K; Imamura H; Matsuyama Y; Kume Y; Ikeda H; Norman GL; Shums Z; Aoki T; Hasegawa K; Beck Y; Sugawara Y; Kokudo N J Gastroenterol; 2010 Dec; 45(12):1272-82. PubMed ID: 20625772 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of Tumor Response Using Alpha-fetoprotein and Des-gamma-carboxy Prothrombin in Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization. Cerban R; Ester C; Iacob S; Paslaru L; Dumitru R; Grasu M; Constantin G; Popescu I; Gheorghe L Chirurgia (Bucur); 2018; 113(4):524-533. PubMed ID: 30183583 [TBL] [Abstract][Full Text] [Related]
19. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Sterling RK; Wright EC; Morgan TR; Seeff LB; Hoefs JC; Di Bisceglie AM; Dienstag JL; Lok AS Am J Gastroenterol; 2012 Jan; 107(1):64-74. PubMed ID: 21931376 [TBL] [Abstract][Full Text] [Related]
20. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Shimada M; Takenaka K; Fujiwara Y; Gion T; Kajiyama K; Maeda T; Shirabe K; Sugimachi K Cancer; 1996 Nov; 78(10):2094-100. PubMed ID: 8918402 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]